| Dr Mark Robert Schlimgen, MD | |
|
1221 Whipple St, Eau Claire, WI 54703-5270 | |
| (715) 552-5346 | |
| Not Available |
| Full Name | Dr Mark Robert Schlimgen |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 32 Years |
| Location | 1221 Whipple St, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285602748 | NPI | - | NPPES |
| 31962300 | Medicaid | WI | |
| 864504300 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 34795 (Wisconsin) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 34795 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System Eau Claire Hospital | Eau claire, WI | Hospital |
| Mayo Clinic Health System-northland | Barron, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-northwest Wisconsin Region Inc | 4385553627 | 623 |
News Archive
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration released the use of gammaCore (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients.
With some California community health centers just weeks or days away from laying off staff or reducing their hours, the state adopted its latest-ever annual budget on Oct. 8.
› Verified 4 days ago
| Entity Name | Pain Clinic Of Northwestern Wisconsin Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609844000 PECOS PAC ID: 2365428893 Enrollment ID: O20040625000814 |
News Archive
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration released the use of gammaCore (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients.
With some California community health centers just weeks or days away from laying off staff or reducing their hours, the state adopted its latest-ever annual budget on Oct. 8.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration released the use of gammaCore (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients.
With some California community health centers just weeks or days away from laying off staff or reducing their hours, the state adopted its latest-ever annual budget on Oct. 8.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1154372944 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000001 |
News Archive
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration released the use of gammaCore (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients.
With some California community health centers just weeks or days away from laying off staff or reducing their hours, the state adopted its latest-ever annual budget on Oct. 8.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740239557 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000112 |
News Archive
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration released the use of gammaCore (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients.
With some California community health centers just weeks or days away from laying off staff or reducing their hours, the state adopted its latest-ever annual budget on Oct. 8.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Robert Schlimgen, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (715) 838-5222 | Dr Mark Robert Schlimgen, MD 1221 Whipple St, Eau Claire, WI 54703-5270 Ph: (715) 552-5346 |
News Archive
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration released the use of gammaCore (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients.
With some California community health centers just weeks or days away from laying off staff or reducing their hours, the state adopted its latest-ever annual budget on Oct. 8.
› Verified 4 days ago
Dr. Stephen Mathias Endres, MD Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-552-5346 |